The NDRG1 Knockout Raji Polyclonal Cells product comprises a polyclonal population of human Raji B lymphoblastoid cells in which the NDRG1 gene has been disrupted via CRISPR/Cas9-mediated genome editing. This knockout model provides a loss-of-function tool to investigate the biological roles of the NDRG1 protein in a B-cell lymphoma context. The polyclonal nature of the knockout pool preserves cellular heterogeneity, making it suitable for population-level studies of gene function without clonal selection bias.
The parental Raji cell line is a well-characterized human B lymphoblastoid line derived from a patient with Burkitt lymphoma. These cells grow in suspension, are Epstein-Barr virus (EBV) positive, and are widely used in immunology and cancer research. Their B-cell origin and EBV status make them an important model for studying lymphomagenesis, viral oncogenesis, and B-cell signaling pathways. Raji cells express multiple surface markers relevant to B-cell biology and are frequently employed in antibody-dependent cellular cytotoxicity (ADCC) assays, drug screening, and genetic perturbation studies.
NDRG1 (N-myc downstream regulated gene 1) is a cytoplasmic protein involved in stress responses, differentiation, and metastasis suppression. It is transcriptionally activated by HIF-1?? under hypoxia and by p53, and is further regulated by androgens, MYC, and TGF-??. NDRG1 potently inhibits epithelial-mesenchymal transition (EMT), reducing cell migration and invasion. Mechanistically, it interacts with 14-3-3 proteins, heat shock proteins (HSC70, HSP90), and Rab4a. Downstream, NDRG1 promotes E-cadherin (CDH1) and PTEN expression while repressing MMP9 and VEGF, thereby attenuating ??-catenin (CTNNB1) and mTOR signaling pathways.
In the Raji B-cell lymphoma background, disruption of NDRG1 offers a unique opportunity to dissect its tumor-suppressive functions in a hematological malignancy, where its role is less defined compared to solid tumors. Given Raji cells express elevated MYC due to the characteristic Burkitt lymphoma translocation, and are subject to hypoxic microenvironments in vivo, this knockout model enables exploration of how NDRG1 modulates MYC-driven oncogenesis and hypoxia response pathways in B cells. Furthermore, because NDRG1 negatively regulates mTOR and ??-catenin pathways, its loss may reveal context-specific dependencies and compensatory signaling mechanisms in lymphoma. This polyclonal knockout pool can also serve as a baseline for studying NDRG1-mediated drug sensitivity, as it has been implicated in resistance to chemotherapeutic agents like doxorubicin.
Researchers can employ this NDRG1 knockout polyclonal cell population to perform a variety of functional assays. Western blotting and RT-qPCR can be used to confirm knockdown of NDRG1 and assess consequent changes in markers such as E-cadherin, MMP9, and ??-catenin. Migration and invasion assays allow direct measurement of metastatic behavior alterations, while flow cytometry facilitates analysis of apoptosis and cell cycle distribution. RNA-sequencing and co-immunoprecipitation experiments permit global transcriptomic profiling and identification of NDRG1 protein interaction networks in B-lymphoma cells. Additionally, drug sensitivity assays with agents like doxorubicin can clarify NDRG1??s impact on chemoresistance. For further technical information, custom services, or to discuss your specific experimental needs, please contact Ascent Research.
